(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 May 2008 (02.05.2008)

PCT

(10) International Publication Number
WO 2008/050821 A1

(51) International Patent Classification:
C07D 417/14 (2006.01) *A61K 31/433* (2006.01)
A61K 31/427 (2006.01) *A61P 3/10* (2006.01)

(21) International Application Number:
PCT/JP2007/070772

(22) International Filing Date: 18 October 2007 (18.10.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2006-285551 19 October 2006 (19.10.2006) JP

(71) Applicant *(for all designated States except US)*: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **YASUMA, Tsuneo** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85,Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5328686 (JP). **UJIKAWA, Osamu** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85,Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5328686 (JP). **ITOH, Masahiro** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85,Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5328686 (JP). **AOKI, Kazuko** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85,Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5328686 (JP).


(74) Agent: **TAKASHIMA, Hajime**; Meiji Yasuda Seimei Osaka Midosuji Bldg., 1-1, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 5410044 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*


(54) Title: INDOLE COMPOUND



(I)



or



(57) Abstract: The purpose of the present invention is to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I):wherein R^1 is a hydrogen atom or a halogen atom; R^2 is a group represented by wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.

WO 2008/050821 A1